Bonserin

Quick links to important sections

Bonserin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonserin

Quick Facts

Property Description
Active Ingredient Mianserin hydrochloride
Form Tablets for oral use
Pharmacological Class Tetracyclic Antidepressant (TeCA)
General Purpose Mood stabilization, easing anxiety, and promoting sleep
Origin Synthetic compound

What is Bonserin and What Type of Drug is it?

Bonserin is a single-component, synthetic pharmaceutical product defined by its active ingredient, Mianserin hydrochloride, a compound used for its effects on mood and neurotransmission. Mianserin is formally classified as a Tetracyclic antidepressant (TeCA), which is an older and chemically distinct class of psychoactive drugs. The compound is often categorized further as an atypical antidepressant and a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA) due to its unique pharmacological profile. The drug is typically supplied as tablets intended for oral use and requires a prescription for dispensing.

Mianserin: Unique Composition and General Purpose

The medication's composition consists of the chemically synthesized Mianserin hydrochloride combined with standard pharmaceutical excipients necessary for forming the tablet. Its overall therapeutic utility is based on its ability to modulate specific brain receptors to help restore chemical balance. Mianserin's primary mechanism involves increasing the availability of the neurotransmitter norepinephrine in the brain, which contributes to stabilizing and improving mood. Crucially, the compound also strongly influences histamine receptors, delivering a significant calming and sleep-aiding effect. This is a differentiating factor compared to many newer antidepressants. The drug's efficacy profile makes it a typical option when treating depressive illness where symptoms include pronounced anxiety, agitation, and insomnia. This indicates that the drug's properties can help relieve the severe agitation and difficulty sleeping that accompany depressive episodes.

What side effects are possible with Bonserin?

Possible side effects and safety information

The safety profile for Bonserin (Mianserin) is defined by official regulatory documents that classify potential adverse reactions based on their frequency and physiological impact.

Frequency-Classified Adverse Reactions

The most frequently documented event is Drowsiness/Sedation, which is classified as Very Common (occurring in ge1/10 patients), often being most pronounced at the start of treatment. Common (occurring in ge1/100 to <1/10 patients) effects include Weight gain, Peripheral Oedema, and Postural hypotension (a drop in blood pressure upon standing). Less frequent events include Convulsions/Seizures (Uncommon) and Mania (Rare).

Clinically Significant Adverse Reactions and Monitoring

The regulatory label documents several rare but serious adverse reactions, primarily categorized under Blood and Lymphatic System Disorders and Hepatobiliary Disorders. The risk of Agranulocytosis (a severe reduction in white blood cells) is classified as Very Rare and is noted to occur most frequently between the 4th and 6th week of treatment. Hepatitis is also listed as a Rare adverse reaction. Furthermore, the risk of Suicidal ideation and behaviour is associated with treatment, especially early on, as noted in official safety documentation for antidepressants.

Population-Specific Safety Constraints

The medication is not recommended for use in children and adolescents under 18 years of age. It is formally contraindicated in individuals with severe hepatic impairment (severe liver disease). Older adults may be more susceptible to events like postural hypotension and require specific supervision due to slower drug clearance.

Regulatory Safety Summary

These official safety data structure the medicine’s risk profile by detailing the probability and type of adverse effects, from common initial sedation to rare but critical events like agranulocytosis. The documented risks establish clear boundaries for use, specifically restricting the medication based on age and pre-existing liver function.

Overdose and Emergency Response

Overdose and When to Seek Help

The information presented here details the officially documented signs and required emergency actions in case of an overdose with mianserin hydrochloride (Bonserin), as stated in governmental regulatory sources.

Overdose primarily affects the Central Nervous System (CNS) and the cardiovascular system. Documented clinical manifestations include somnolence (drowsiness), sedation, tachycardia (rapid heart rate), hypertension, and hypotension.


Severe Outcomes and Emergency Action

In severe cases, overdose can progress to life-threatening outcomes such as coma and respiratory depression. Seizures and fatal outcomes have been reported, particularly when mianserin is ingested in combination with other substances. Overdose in children has also been reported to result in respiratory depression and coma.


Required Emergency Response

Immediate medical attention must be sought for any suspected overdose. Due to the potential for severe effects, admission to a hospital is required for close observation and continuous monitoring of cardiac function and vital signs.

Official labeling confirms that no specific antidote is known for mianserin. Therefore, treatment is strictly symptomatic and supportive. Supportive measures officially described include the potential use of gastric lavage and activated charcoal administration in the emergency setting.

Therapeutic Uses of Bonserin

What Bonserin Treats: Main Uses and Benefits

Bonserin (Mianserin) is commonly used to provide symptomatic relief for depressive illness when the condition is accompanied by highly disruptive manifestations like severe anxiety and insomnia. Its therapeutic approach supports stabilizing mood while specifically addressing acute symptoms that may interfere with daily functioning and patient comfort.

The medication is indicated for the treatment of primary depressive illness, including cases like endogenous, reactive, and involutional melancholia, and is commonly used for managing symptoms when marked anxiety or insomnia is a predominant feature. The primary therapeutic application is the treatment of major depressive illness and related depressive states. The drug is considered relevant for managing pervasive feelings of low mood, managing prominent anxiety and psychomotor agitation, and supporting restorative sleep by addressing associated insomnia. It is considered relevant in clinical settings when the patient requires additional symptomatic support for sleep and tension.


Quick Fact: Relief for Co-Occurring Symptoms

Symptom Domain Key Benefit Provided
Low Mood & Sadness Supports emotional stability and contributes to easing the overall symptom load.
Anxiety & Agitation Assists in managing inner tension by providing a strong calming effect.
Insomnia Supports restorative sleep and may assist with maintaining functional stability.

Regulatory References

  1. Official Summary of Product Characteristics for Mianserin

Eligibility and Restrictions for Use

Who Can and Cannot Use Bonserin?

Regulatory guidelines strictly define the population groups eligible for Bonserin (Mianserin), based on age, existing health conditions, and physiological status.

Eligibility Group Regulatory Status
Adults (18+ years) Approved for use in major depressive illness.
Older Adults Permitted, but requires a lower initial dose and careful adjustment.
Children/Adolescents Not recommended; safety and efficacy are not established below 18 years.
Pregnant Women Not recommended; use only if the potential benefit outweighs the risk to the fetus.
Breastfeeding Women Contraindicated in some regions and generally not recommended.

Contraindicated Populations

Bonserin must not be used in patients with severe liver disease/hepatic impairment or those experiencing mania/hypomania. The medicine is also strictly prohibited for individuals with a known hypersensitivity to mianserin or who are currently taking Monoamine Oxidase Inhibitors (MAOIs) or have stopped MAOIs within the last two weeks.

Condition-Based Restrictions

Conditional use with caution and close supervision is required for patients with a history of epilepsy, certain cardiovascular conditions (like heart block or recent myocardial infarction), renal impairment, or diabetes mellitus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Mianserin (Bonserin) details specific pharmacokinetic and pharmacodynamic interactions that must be acknowledged prior to co-administration. Certain medicinal combinations are formally contraindicated in government labeling. This includes co-administration with Monoamine Oxidase Inhibitors (MAOIs), which requires a two-week separation period before starting Mianserin therapy. A shorter one-week separation period is mandated when switching from the reversible MAO-A inhibitor Moclobemide.

Pharmacokinetic and Pharmacodynamic Interaction Patterns

Co-administration with enzyme-accelerating medicines, such as Carbamazepine and Phenobarbital, is documented to accelerate the metabolism of Mianserin, resulting in reduced plasma concentration of the drug. From a pharmacodynamic perspective, Mianserin may potentiate the central nervous depressant action when taken with substances like Alcohol, anxiolytics, hypnotics, and antipsychotics. This potentiation also extends to enhanced hypotensive effects when combined with specific antihypertensives. Additionally, the drug may antagonise the anticonvulsant effect of antiepileptic medicines. For elderly patients, regulatory information notes a longer half-life and slower metabolite clearance, which must be considered when evaluating potential accumulation or interaction effects.

Mechanism of Action

H1 Antagonism: Rapid Onset Suppression of Arousal and Vigilance

Bonserin's active component, Mianserin, exerts a key action through high-affinity antagonism of the central Histamine mathbfH1 receptor. By blocking H1 activity, the drug rapidly suppresses the CNS arousal system, leading to a swift dampening of central vigilance and induction of a sedative physiological state. This interaction results in a rapid physiological consequence.


alpha2 Antagonism: Disinhibition and Sustained Monoamine Elevation

This mechanism involves the antagonism of presynaptic mathbfalpha2 -adrenergic receptors, which normally function as an inhibitory brake on neurotransmitter release. The removal of this inhibition, a process termed disinhibition, results in a sustained increase in the synaptic availability of both Norepinephrine and Serotonin. The resulting physiological effect is a gradual and long-term modulation of affective circuitry, a process which requires chronic neuronal adaptation to fully manifest.

Dosage and Administration Information

How to Use Bonserin

Bonserin, which contains Mianserin hydrochloride, is an oral medication administered in tablet form. The prescribed usage pattern defines the dose range, frequency, and specific administration conditions.

Standard Dosing and Administration

The standard approach for adult patients involves starting treatment with a low dose, typically 30 mg or 40 mg per day. The dosage is then gradually adjusted based on the patient’s response, working toward a typical effective maintenance range of 30 mg to 90 mg daily. The maximum daily dose is 120 mg.

The medication is most often taken as a single dose at night because of its effects on sleep, although the total daily dose may also be split into divided doses. Tablets must be swallowed whole with fluid and should not be chewed. The tablets are typically taken between meals.

Duration and Specific Population Use

Treatment is typically maintained for several months after the initial clinical effect is achieved. When discontinuing the medication, the treatment must not be stopped suddenly; the dosage must be gradually reduced over time.

Usage instructions are modified for certain populations. For older adults (over 65), the initial dose should not exceed 30 mg daily, and a single night-time dose is often preferred. The medication should not be used in patients under 18 years of age due to lack of established use protocols in this group. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose; a double dose must never be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Chronic Pain Management Studies

Studies have evaluated the management of chronic pain.

  • Primary Efficacy Data: A multi-center Randomized Controlled Trial (RCT) involving 450 participants studied the compound over a 12-week period.
  • Key Findings: A key finding indicated a difference in average weekly pain scores, and the study assessed the time point of first measurement change. There was no comparison to other standard-of-care treatments in this study.
  • Long-Term Follow-up: An open-label extension study followed 150 of the original participants for an additional six months to assess the durability of the initial observations.

Combination Therapy Trials

Studies evaluated combination therapy and compared the outcomes with monotherapy. These studies focused on patients with refractory chronic pain.

  • Synergy Research: The combination of both active compounds was investigated for its association with the frequency of flare-ups. This study compared outcomes in groups receiving Compound A alone, Compound B alone, and the combination.
  • Trial Protocol: Trial design specified a consistent administration time; the study assessed the measured outcomes under these specific conditions. These protocols primarily aimed for consistent drug levels in study participants.

Safety and Special Populations

Research evaluated potential risks in populations with specific pre-existing conditions and examined the tolerability profile.

  • Hepatic Impairment: Research evaluated use in individuals with mild hepatic impairment. The study monitored liver function tests and adverse events, noting that the exposure levels of the drug were not substantially altered in this population.
  • Cardiovascular Risk: Research evaluated potential risks in populations with a history of hypertension. The study monitored blood pressure and heart rate changes over the treatment period.
  • Adverse Event Profile: Across all clinical trials, the most commonly reported adverse events included mild nausea, headache, and fatigue. The study protocols described these events as generally transient.

Off-Label Explorations

Studies explored the use across a range of pain conditions, including osteoarthritis and neuropathic pain. It is not yet clear whether the study findings in these specific conditions align with the primary chronic pain indications.

Key Studies & References

  1. Bonserin-SPC-Aug_2024-03 (Regulatory document/Summary of Product Characteristics providing safety, hepatic, and dosing context)

Frequently Asked Questions (FAQ)

Common questions about Bonserin (FAQ)

Q: Does Bonserin cause weight gain or weight loss?

A: According to official product information, weight gain and an increase in appetite are reported as common side effects of this medication. Weight loss is not typically listed as a documented adverse effect. This information is based on data collected during clinical trials.

Q: Is Bonserin safe for long-term use?

A: Treatment with this medication is typically maintained for several months after the initial effects are achieved. Due to the small but serious risk of rare side effects, such as changes in blood cell count (blood disorders) or liver function, long-term use requires careful and regular monitoring by a healthcare professional.

Q: What is the legal classification or schedule of Bonserin?

A: Bonserin is classified as a prescription-only medicine. Unlike some other medications, it is generally not scheduled as a controlled substance with a high potential for abuse or dependence under regulatory acts like the U.S. Controlled Substance Act.

Q: Can I drive or operate machinery while taking Bonserin?

A: Official product information states that drowsiness is the most common side effect, which is often pronounced when first starting the medication. Because of this effect on alertness, regulatory guidance includes a warning about the possible hazard in driving or operating machinery.

Q: Are there any specific foods or drinks I need to avoid while on Bonserin?

A: Regulatory product information does not generally mandate the avoidance of specific foods. However, official regulatory documents state that use with alcohol is not recommended, as alcohol can potentiate the central nervous system depressant and drowsiness effects of the medication.

Q: Do studies suggest Bonserin is effective for all people who take it?

A: While clinical trials have demonstrated that the medication is effective in studied populations, official information acknowledges that individual response can vary. As with any medication, effectiveness for every person is not guaranteed.

Q: Is Bonserin used for anything other than its main approved condition?

A: The official and approved therapeutic use of this medication is strictly for the treatment of major depressive illness. The regulatory label and official product information do not describe or support its use for any other medical conditions.

Q: Can Bonserin affect the results of common blood tests?

A: Yes, because of the rare but serious risk of specific blood disorders, like agranulocytosis (a severe reduction in white blood cells), regulatory guidelines recommend regular monitoring. This typically involves a full blood count test, particularly during the initial three months of treatment.

Q: What is the difference between the various strengths or forms of Bonserin?

A: Bonserin is typically supplied as oral tablets. To allow for customized treatment based on individual needs and response, the tablets are made available in multiple dosage strengths.

Q: What are the most frequently reported serious side effects for Bonserin?

A: Serious but rare adverse effects include specific blood disorders (like agranulocytosis) and changes in liver function. Additionally, official safety documents note that suicidal thoughts and behavior are associated with treatment, especially at the start, as is the case with many antidepressants.

Q: Does Bonserin have a risk of withdrawal symptoms when discontinued?

A: Official guidelines reflect that the dosage must be gradually reduced and not stopped suddenly, particularly after long-term use. This required tapering process is implemented because withdrawal reactions may occur, which are typically reported as mild and temporary, and can include nausea, dizziness, and anxiety.

Q: What is the half-life of Bonserin?

A: According to official pharmacokinetic information, the terminal elimination half-life (the time it takes for half the drug to be cleared from the body) is typically around 9 to 10 hours for young adults. This half-life may be significantly longer in older adults.

Q: Can Bonserin be taken with common over-the-counter pain relievers?

A: Official product information does not specifically name common non-prescription pain relievers. However, due to the potential for interactions, regulatory warnings require that a healthcare professional review all co-administered medications, particularly those that act as central nervous system (CNS) depressants.

Q: Is Bonserin known to be addictive or habit-forming?

A: Official regulatory classification confirms that Mianserin is not typically classified as a controlled substance. Therefore, it does not carry a high potential for abuse or dependence.

Q: What should I do if the side effects of Bonserin feel too strong?

A: If any adverse effects feel excessively bothersome, or if signs of serious adverse reactions—such as fever, sore throat, or unusual changes in behavior—are noted, regulatory warnings indicate that immediate professional medical attention is required. This urgency is emphasized for rare but serious side effects that demand close monitoring.

Q: Why is Bonserin considered a prescription-only medicine?

A: This medication is prescription-only primarily due to its risk profile, which necessitates careful supervision. The required prescription ensures that specific medical conditions are diagnosed, rare but serious side effects are monitored, and the dosage is adjusted precisely to the patient's needs.

Q: What should be done if an allergic reaction to Bonserin is suspected?

A: Hypersensitivity reactions to the active ingredient are known contraindications for use. If a serious allergic reaction is suspected, such as facial swelling, difficulty breathing, or severe rash, regulatory warnings state that immediate emergency medical attention is required.

Q: Does Bonserin interact with herbal remedies like St. John's Wort?

A: Official documents caution against taking the medication with certain drug classes. Because some herbal remedies, such as St. John’s Wort, can affect neurotransmitter levels, regulatory standards require that a healthcare professional fully review all herbal and natural supplements before co-administration with this medication.

Q: Is Bonserin known to affect fertility in men or women?

A: Based on regulatory hazard information for the active ingredient, the substance is officially categorized as suspected of damaging fertility.

Q: Does Bonserin have any known effects on vision or eyes?

A: Official product information notes that some patients have experienced visual disturbances while taking the medication, including blurred vision. Any persistent or severe changes to vision are required to be reported to a healthcare provider for assessment.

Q: Is there a risk of overdose with Bonserin?

A: Overdosage is possible with this medication. The symptoms of overdose are typically limited to prolonged states of severe drowsiness or sedation. In such cases, there is no specific antidote, and treatment consists of supportive care and managing the symptoms.

Q: Can Bonserin be taken with common cold and flu medications?

A: Many common cold and flu medications contain ingredients that can affect the central nervous system (CNS) or blood pressure. Since this medication can intensify the effects of CNS depressants and enhance blood pressure lowering effects, regulatory warnings require that a healthcare professional review all concurrent use of cold and flu medicines.

How should Bonserin be stored and disposed of?

Storage Conditions and Packaging

Bonserin (mianserin hydrochloride) tablets must be stored at a temperature below 25 °C to maintain the product’s integrity. The medication should be kept in the original package to ensure it is protected from light and moisture. To prevent accidental ingestion, the tablets must be stored in a secure location and kept out of the sight and reach of children and pets. The medicine should not be used after the expiry date printed on the packaging, as the official shelf-life under these conditions is 3 years.


Disposal Instructions

For disposal of unused or expired Bonserin, the official requirement is to utilize an approved waste disposal plant or a designated drug take-back program. It is strictly stated that the medicine's discharge into the environment must be avoided, meaning it should not be thrown into household trash or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bonserin found in:

A-Z Index: